MedPath

A Clinical Study of Vaginal Lubricant for Improvement of Vaginal Dryness

Phase 3
Completed
Conditions
Health Condition 1: N952- Postmenopausal atrophic vaginitis
Registration Number
CTRI/2018/01/011142
Lead Sponsor
The Himalaya Drug Company
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
40
Inclusion Criteria

Women with active sex lives of at least one sexual intercourse in a week

Women without a history of sensitivity to similar formulations

Subjects willing to sign informed consent and follow the study procedure.

Exclusion Criteria

Women using other intra vaginal gel moisturizer, diagnosed with cancer, Women using hormone replacement therapy in the last 3 months, Absence of history or visible evidence of chronic skin disease or regional infections, genital herpes, vaginal infections or urinary tract infection, Pregnant or lactating, women likely to become pregnant, Personal history of allergy and hypersensitivity to any product of feminine hygiene, severe systemic complications of viral infections, severe systemic illness like cardiovascular disorders, neurological disorders, renal disorders, autoimmune disorders,Not willing to sign informed consent form

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percentage of improvement of vaginal dryness symptoms. Change of Verbal Rating Scale (VRS) total score from baseline to the end of the study.To evaluate the differences from baseline to the end of the study of Female Sexual Function Index (FSFI) and Female Sexual Distress Scale (FSDS-R) <br/ ><br>Timepoint: Visit 0- At entry visit, baseline <br/ ><br>Visit 1- At the end of Week 2 <br/ ><br>Visit 2- At the end of Week 4 <br/ ><br>
Secondary Outcome Measures
NameTimeMethod
Incidence of adverse events (AEs) <br/ ><br>Safety and Tolerability of the study drug and patient compliance to therapyTimepoint: Visit 0- At entry visit, baseline <br/ ><br>Visit 1- At the end of Week 2 <br/ ><br>Visit 2- At the end of Week 4
© Copyright 2025. All Rights Reserved by MedPath